💊 The ₹75,000 Question That Shook India's Patent System

🌟 Imagine you've invented a life-saving cancer drug. You have a patent. But what if that patent becomes a wall between desperate patients and affordable treatment? This episode explores the fascinating clash between innovation rights and public health.

💡 What You'll Discover:

• 🔍 Why having a patent isn't enough - you must actually "work" it in India
• ⚖️ How compulsory licensing can break patent monopolies for public good
• 🎯 The difference between importing medicines vs. manufacturing them locally
• 💰 Why pricing can make or break your patent protection

🚀 Real Cases Discussed:

• 💎 Bayer Corporation vs. Union of India (2014) - The landmark case where a ₹84,000 cancer drug met its ₹8,800 competitor
• ⭐ Natco Pharmaceuticals' Compulsory License - How an Indian company legally broke Bayer's monopoly
• 🏛️ Intellectual Property Appellate Board (IPAB) - The tribunal that sided with affordable medicine

🧠 The Feynman Breakdown:

• 🔬 Industrial Application - Think of it as "Does your invention actually help people in the real world?"
• 🏭 Working a Patent - Like owning a restaurant but never serving food - what's the point?
• ⚡ Compulsory Licensing - The legal "emergency brake" when patents harm public interest

🎙️ By the end, you'll understand how India balances rewarding inventors with ensuring life-saving medicines reach those who need them most - a lesson in law, ethics, and human compassion!